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Abstract: BACKGROUND Temporal muscle thickness (TMT) was described as surrogate marker of
skeletal muscle mass. This study aimed to evaluate the prognostic relevance of TMT in patients with
progressive glioblastoma. METHODS TMT was analyzed on cranial magnetic resonance images of 596
patients with progression of glioblastoma after radio-chemotherapy enrolled in the EORTC 26101 trial.
An optimal TMT cutoff for overall survival (OS) and progression free survival (PFS) was defined in
the training cohort (n=260, phase 2). Patients were grouped as ”below” or ”above” the TMT cutoff
and associations with OS and PFS were tested using the Cox model adjusted for important risk factors.
Findings were validated in a test cohort (n=308, phase 3). RESULTS An optimal baseline TMT cutoff
of 7.2 mm was obtained in the training cohort for both OS and PFS (AUC=0.64). Univariate analyses
estimated a hazard ratio (HR) of 0.54 (95% CI: 0.42, 0.70, p<0.0001) for OS and a HR of 0.49 (95%
CI: 0.38, 0.64, p<0.0001) for PFS for the comparison of training cohort patients above versus below
the TMT cutoff. Similar results were obtained in Cox models adjusted for important risk factors with
relevance in the trial for OS (HR of 0.54, 95% CI: 0.41, 0.70, p<0.0001) and PFS (HR of 0.47, 95% CI:
0.36, 0.61, p<0.0001). Results were confirmed in the validation cohort. CONCLUSION Reduced TMT is
an independent negative prognostic parameter in patients with progressive glioblastoma and may help to
facilitate patient management by supporting patient stratification for therapeutic interventions or clinical
trials.
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Abstract   
Background: Temporal muscle thickness (TMT) was described as surrogate marker of 
skeletal muscle mass. This study aimed to evaluate the prognostic relevance of TMT in 
patients with progressive glioblastoma. 
Methods: TMT was analyzed on cranial magnetic resonance images of 596 patients with 
progression of glioblastoma after radio-chemotherapy enrolled in the EORTC 26101 trial. An 
optimal TMT cutoff for overall survival (OS) and progression free survival (PFS) was defined 
in the training cohort (n=260, phase 2). Patients were grouped as “below” or “above” the 
TMT cutoff and associations with OS and PFS were tested using the Cox model adjusted for 
important risk factors. Findings were validated in a test cohort (n=308, phase 3). 
Results: An optimal baseline TMT cutoff of 7.2 mm was obtained in the training cohort for 
both OS and PFS (AUC=0.64). Univariate analyses estimated a hazard ratio (HR) of 0.54 
(95% CI: 0.42, 0.70, p<0.0001) for OS and a HR of 0.49 (95% CI: 0.38, 0.64, p<0.0001) for 
PFS for the comparison of training cohort patients above versus below the TMT cutoff. 
Similar results were obtained in Cox models adjusted for important risk factors with relevance 
in the trial for OS (HR of 0.54, 95% CI: 0.41, 0.70, p<0.0001) and PFS (HR of 0.47, 95% CI: 
0.36, 0.61, p<0.0001). Results were confirmed in the validation cohort. 
Conclusion: Reduced TMT is an independent negative prognostic parameter in patients with 
progressive glioblastoma and may help to facilitate patient management by supporting patient 
stratification for therapeutic interventions or clinical trials.  
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• TMT is an independent prognostic parameter in patients with progressive 
glioblastoma. 
• TMT is a fast and easily assessable parameter on routine MR images of the brain. 
• TMT may help to objectively define frail patient populations.  
 
Importance of the study  
Besides molecular and histopathological determinants, patients’ frailty is a key parameter to 
be taken into account for patient stratification. However, clinical frailty parameters are mainly 
subjective and markers to objectively define patients’ frailty are urgently needed. Temporal 
muscle thickness (TMT) has been shown to be a suitable surrogate marker for skeletal muscle 
mass and therefore a potential parameter to determine sarcopenia, which is known to have an 
impact on the outcome of cancer patients. Here we show in a large and well-characterized 
cohort of patients treated in a prospective clinical trial with the use of an independent 
validation set that TMT is an independent and strong prognostic parameter in patients with 
progressive glioblastoma. TMT may serve as objectively assessable surrogate parameter of 
sarcopenia and patient frailty that may facilitate patient selection and stratification for 









AUC  area under the curve 
BMI   body mass index 
CI  confidence interval 
CT   computed tomography 
FP  false positive 
HR  hazard ratio 
MGMT O6-methylguanine DNA methyltransferase 
MRC  Medical Research Council 
MRI  magnetic resonance imaging 
OS  overall survival  
PFS  progression-free survival 
ROC  receiver operator curve 
TMT   temporal muscle thickness 
TP  true positive 







Glioblastoma is the most frequent primary malignant brain tumor in adults and is associated 
with high morbidity and mortality.1 Almost all patients experience progression within one 
year despite multimodal first-line therapy consisting of maximal safe surgery and combined 
radio-chemotherapy with the alkylating agent temozolomide.2 Current studies evaluate the 
clinical benefit of various targeted agents and immunotherapies in newly diagnosed and 
progressive glioblastoma. Accurate patient stratification based on reliable prognostic 
parameters is crucial for clinical trial conduct and decision-making in clinical patient 
management.  
Individualized therapy planning in oncology involves consideration of several parameters 
including molecular and histological tumor characteristics, tumor location and size as well as 
patient’s overall physical condition. Most of these parameters are objectively assessable, 
however, particularly the determination of the patients’ clinical condition is influenced by the 
subjective evaluation of the attending physician resulting in a high inter-observer variability 
and lack of accuracy in survival prediction.3,4 Therefore, objectively measurable parameters to 
evaluate patients frailty are required to improve prognostic assessment. An emerging 
parameter to objectively determine patient`s physical condition is the assessment of skeletal 
muscle mass. A reduction of skeletal muscle mass is defined as sarcopenia, which is a key 
feature of cancer-related cachexia.5  
Sarcopenia has been described as an objectively measurable parameter indicating frailty and 
adverse prognosis in several extracranial cancer types6–8. It is usually determined by 
measurement of the skeletal muscle cross-sectional area at the level of third lumbar vertebrae 
on computed tomography (CT) scans, but has not been investigated in glioblastoma so far. 





these images are usually not required and consequently not available in brain tumor patients. 
To perform CT scans exclusively to assess information about patients’ skeletal muscle mass 
would result in increased radiation exposure and additional healthcare costs and is therefore 
not feasible. However, recently published studies revealed a high correlation of lumbar 
skeletal muscle cross-sectional areas with temporal muscle thickness (TMT) obtained on 
routine diagnostic brain MR images, indicating that not exclusively lumbar muscles but also 
cranio-facial muscles may be a useful surrogate parameter for the estimation of skeletal 
muscle mass.9,10 Swartz et al. used the cross-sectional area of skeletal muscles at the third 
cervical vertebra on head and neck CT images to determine sarcopenia in head and neck 
cancer patients.11 Recently, TMT has been shown to be an independent prognostic parameter 
in patients with newly diagnosed brain metastases of melanoma, breast cancer and non-small 
cell lung cancer. TMT may thus serve as an objectively measurable surrogate parameter for 
patient frailty and survival prognosis in patients with brain tumors.12,13 
In the current study, we investigated the prognostic role of TMT in progressive glioblastoma. 
To this end, we retrospectively analyzed TMT in patients enrolled in the international, 
prospective, randomized clinical trial European Organisation for Research and Treatment of 










Material and Methods 
Patient cohorts 
We used all clinical data (including treatment group, overall and progression-free survival 
data, known prognostic variables for survival, and explanatory variables for TMT) that were 
available for all patients with first recurrence of glioblastoma who were treated in the EORTC 
26101 trial (Supplementary Table 1). Study design and outcome of this trial have been 
published.14 EORTC 26101 trial was initially designed as four-arm phase 2 trial designed to 
evaluate to most effective sequence of bevacizumab, a monoclonal antibody targeting 
vascular endothelial growth factor (VEGF), and the chemotherapeutic lomustine at first 
recurrence of glioblastoma. Close to the completion of the EORTC 26101 study, data from 
the BELOB phase II trial indicated an overall survival benefit of the combination of 
bevacizumab and lomustine over either of these agents alone.15 As a consequence, the 
ongoing EORTC 26101 phase 2 trial was modified into a two-arm phase 3 trial enrolling 
patients in one group receiving lomustine as a single agent and one group receiving the 
combination of lomustine and bevacizumab. The final results of the phase 3 EORTC 26101 
trial showed prolonged progression-free survival, but no overall survival advantage with 
combined treatment of bevacizumab and lomustine over lomustine monotherapy in 
progressive glioblastoma. For the current study, we used all 260 patients enrolled in the phase 
2 part of the EORTC 26101 study as a training cohort and all 308 patients enrolled in the 
phase 3 part as a test cohort to determine the correlation of TMT measured at baseline with 
progression-free survival and overall survival in progressive glioblastoma (Supplementary 
Table 1).  This patient stratification design has been selected because it was considered 
to be more dissimilar and independent, due to the different phases of the trial separated 





phase 3 part of the EORTC 26101 study and performing a random split into training 
and test datasets.  
Patients provided written informed consent for translational research and ethics committee 
approval was obtained. 
 
TMT assessment on cranial MR images 
For the present study, we retrospectively retrieved the baseline MR images obtained at 
enrollment into EORTC 26101 before initiation of study treatment. Baseline information on 
TMT was available for 568 of 596 patients (95.3%) which were used for subsequent analyses. 
A total of 28 of 596 patients (4.7%) were excluded from further analyses due to unavailability 
(n=5) or inadequacy (motion artifacts, n=8; only partial depiction of both temporal muscles, 
n=7; or prior therapeutic intervention with bilateral involvement of the temporal muscle, n=8) 
of MRI examinations (Supplementary Figure 1). 
The measurements were performed on axial isotropic (1x1x1 mm) contrast-enhanced T1-
weighted MR images without fat-saturation perpendicular to the long axis of the temporal 
muscle at the level of the Sylvian fissure (anterior-posterior landmark) and the orbital roof 
(cranio-caudal landmark).12,13 The MRI plane was oriented parallel to the anterior 
commissure-posterior commissure line. TMT was measured by a board-certified radiologist 
(JF) who was blinded to all clinical patient characteristics including clinical outcome 
measures (OS and PFS). The measurements were assessed on the left and on the right side 
separately and were further summed up and divided by two, resulting in a mean TMT per 
patient. If there were any signs of previous intervention on one side that could affect the 





or subsequent muscle atrophy), this side was excluded from the measurements and only the 
temporal muscle of the other side of this patient was used for further analysis. If both 
temporal muscles showed post-treatment changes, the patient was excluded from this 
retrospective study.  
Statistical Analysis  
Training cohort  
The training cohort comprised 260 patients enrolled in the phase 2 part of the EORTC 26101 
trial. Time-dependent ROC analyses were used to identify an optimal cutoff in function of OS 
and PFS. Predictions for an event were made at the respective median survival times. The 
optimal cutoff point was defined as the value that maximizes the Younden’s index (i.e. value 
for which sensitivity + specificity - 1 is maximal). Only ROC curves with an AUC > 0.6 were 
considered. Hereafter, patients were grouped as “below” or “above” the TMT cutoff, which 
was visualized by a Kaplan Meier plot separating the TMT cutoff groups. Its association with 
OS and PFS was tested in a univariate Cox model. A two-sided 5% significance level was 
used to determine significance of the results.  
This step was repeated in a multivariate model to check whether the possible effect of TMT 
was not confounded by important prognostic variables. The multivariate model for OS and 
PFS was constructed through automated stepwise backward selection of possible prognostic 
variables (excluding TMT) with a 5% p-value threshold. The multivariate Cox model for PFS 







The test cohort comprised 308 patients enrolled in the phase 3 part of the EORTC 26101 trial 
and was used to validate the findings of the analyses performed in the training cohort. Patients 
in the test cohort were classified as “below” or “above” the TMT cutoff obtained in the 
training cohort. A log-rank test was performed, visualized by a Kaplan Meier plot separating 
the TMT cutoff groups. The association between with OS and PFS was again tested in the 
uni- and multivariate Cox model. In order to be validated, the association had to be of the 
same magnitude as the effect in the training cohort and unidirectional. A two-sided 5% 
significance level was used to determine significance of the results. Sensitivity and specificity 
were used as a measure for discriminative ability of the model. 
Training and test cohort 
Continuous variables were presented by their median and quartiles. Categorical variables 
were presented as frequencies and percentages. A difference of 10% was considered clinically 
relevant.  
The correlation with mean TMT and possible explanatory variables was obtained by 
Spearman rank correlation method for continuous variables (BMI and age) and √𝑅𝑅2 obtained 
through univariate linear models for categorical variables (gender, WHO performance status, 
and steroid use). A correlation coefficient of at least +/-0.3 (weak correlation) was predefined 
as threshold. 
Univariate Cox regression analysis in function of mean TMT as a continuous covariate was 








Patient and clinical characteristics 
The training cohort consisted of 260 patients and the test cohort comprised 308 patients. The 
prevalence of baseline patient and clinical trial characteristics was similar for the training and 
test cohort except for treatment arm and phase (by default) and maximum diameter of the 
target lesion, when considering a difference of 10% as clinically relevant (see 
Supplementary Table 1). Patients in the training cohort had more often a target lesion ≥ 40 
mm diameter than patients in the test cohort: 52.7% vs 42.2%. In both the training and test 
cohort median OS was approximately 9 months and median PFS was approximately 3 months 
(see Supplementary Figure 2). Due to staged study design, median follow-up was longer in 
the training cohort (approximately 30 months) than in comparison to the test cohort 
(approximately 12 months).  
Training cohort 
In the training cohort, 194 of 260 patients (75%) had measurements for left TMT and 163 of 
260 patients (63%) had measurements for right TMT. For 97 of 260 patients (37%) 
observations for both left and right TMT were available (Pearson correlation coefficient was 
0.93). Median TMT was 7.1 mm (Q1: 2.6 – Q3: 12.0) for the left side, 7.2 mm (Q1: 3.5 – Q3: 
12.7) for the right side, and 7.1 mm (Q1: 2.6 – Q3: 12.4) for the mean TMT.  
Figure 1 represents examples of TMT measurements on T1-weighted contrast-enhanced MR 
images. 
There was no relation between mean TMT and any of the explanatory variables as none of the 
correlation coefficients passed the predefined threshold of 0.3. The correlation between mean 





A univariate Cox model for OS and PFS in function of mean TMT in mm as a continuous 
variable resulted in HR of 0.79 (95% CI: 0.72 – 0.86, p<0.0001) and 0.77 (95% CI: 0.71 – 
0.84, p<0.0001). The association of mean TMT with outcome was approximately linear 
(results not shown).  
The time-dependent ROC analysis for OS at 9 months and for PFS at 3 months, 
discriminating between patients with an event and those who remained event-free, resulted in 
ROC curves with AUC = 0.64 (Supplementary Figure 3). The optimal cutoff point for mean 
TMT corresponded to 7.2 mm for both OS and for PFS, with a true positive (TP) rate of 65% 
and a false positive (FP) rate of 36% for OS at 9 months and a TP rate of 63% and a FP rate 
of 35% for PFS at 3 months. 
The cutoff value was further used to divide the training cohort in two groups. Hereafter, 132 
patients (50.8%) had mean TMT values below the cutoff (i.e. <7.2 mm) whereas the TMT 
values of 128 patients (49.2%) were above the cutoff (i.e. ≥7.2 mm). 
Kaplan Meier curves for OS and PFS separating patients with mean TMT values below (red 
line) and above (blue line) the cutoff are visualized in Figure 2a and Figure 2b.   
A univariate Cox model for OS in function of the TMT cutoff resulted in a HR of 0.54 (95% 
CI: 0.42, 0.70, p<0.0001). Similar results were obtained with the multivariate Cox model (HR 
of 0.54, 95% CI: 0.41, 0.70, p<0.0001). Significant prognostic variables for OS were steroid 
use at baseline, HR of 1.58, 95% CI: 1.19, 2.11, p = 0.002; MGMT Status, HR of 0.51, 95% 
CI: 0.36, 0.72, p<0.001; maximum diameter ≥ 40mm, HR of 2.49, 95% CI: 1.41, 4.41, p = 
0.002; central hemisphere involvement, HR of 1.97, 95% CI: 1.37, 2.84, p<0.001 
(Supplementary Table 3). 





year which indicates non-proportionality of TMT curves hazards. Because of the violation of 
the proportionality assumption (Grambsch and Therneau test; p=0.036) a sensitivity analysis 
was performed whereby OS was censored at 12 months. The truncated univariate Cox model 
for OS in function of the TMT cutoff resulted in a HR of 0.43 (95% CI: 0.31, 0.59, 
p<0.0001). The same result was obtained with the truncated multivariate Cox model 
(Supplementary Table 4).  
A univariate Cox model for PFS in function of the TMT cutoff resulted in a HR of 0.49 (95% 
CI: 0.38, 0.64, p<0.0001). Similar results were obtained for the use of the TMT cutoff in a 
multivariate Cox model for PFS which was stratified for treatment arm (HR of 0.47, 95% CI: 
0.36, 0.61, p<0.0001). Important prognostic variables for PFS were neurological deficit, HR 
of 1.44, 95% CI:1.09, 1,92, p = 0.011; steroid use at baseline, HR of 1.42, 95% CI: 1.08, 1.86, 
p = 0.011; MGMT status, HR of 0.61, 95% CI: 0.43, 0.87, p = 0.007; number of target lesion 
>1, HR of 2.47, 95% CI: 1.38, 4,41, p = 0.002 (Supplementary Table 5).  
Test cohort 
Next we tried to confirm the findings of the training cohort in the test cohort. Of 308 patients 
of the test cohort, 217 patients (70.5%) had mean TMT values below the TMT cutoff (i.e. 
<7.2 mm) and 91 patients (29.5%) had mean TMT values above the cutoff (i.e. ≥7.2 mm). 
Kaplan Meier curves for OS and PFS separating patients in the test cohort with mean TMT 
values below and above the cutoff of 7.2 mm are shown in Figure 3a and 3b (log-rank test 
p<0.0001), both for OS and PFS). 
A univariate Cox model for OS in function of the TMT cutoff resulted in a HR of 0.44 (95% 
CI: 0.32, 0.61, p<0.0001). Similar results for the TMT cutoff were obtained with the 
multivariate Cox model (HR of 0.43, 95% CI: 0.31, 0.60, p<0.0001; Supplementary Table 





Grambsch and Therneau test (p=0.18), therefore no additional sensitivity analyses were 
performed. The TMT cutoff of 7.2 mm resulted in a TP rate of 82% and a FP rate of 58% for 
OS at 9 months (Supplementary Figure 4a). A univariate Cox model for PFS in function of 
the TMT cutoff resulted in a HR of 0.46 (95% CI: 0.35, 0.61, p<0.0001). Similar results were 
obtained in the multivariate Cox model stratified for treatment arm (HR = 0.50, 95% CI: 0.37, 
0.66, p<0.0001, Supplementary Table 7). The mean TMT cutoff of 7.2 mm resulted in a TP 










This study investigated the prognostic value of TMT in patients with glioblastoma at first 
progression after standard combined radiochemotherapy. We show a strong and independent 
prognostic role of TMT for PFS and OS. In Cox models, the risk of death and progression or 
death was increased by 85% and 113% in patients with a TMT below the cut-off compared to 
patients with a TMT above the cut-off in the training cohort (Figure 2, Supplementary Table 3 
and 5). The findings of the training cohort were validated in the test cohort. Herein, the risk of 
death and progression or death was increased by 127% and 100%, (Figure 3, Supplementary 
Table 6 and 7) when comparing patients below and above the optimal TMT cutoff. These data 
confirm and extend findings in brain metastases patients. TMT showed a strong association 
with OS at the diagnosis of brain metastases. In melanoma, non-small cell lung cancer and 
breast cancer patients the risk of death was increased by 39%, 32% and 24%, respectively, 
when comparing patients below and above the TMT cutoff, which was 5.8 mm in melanoma 
patients, 5.9 mm in non-small cell lung cancer patients and 5.4 mm in breast cancer 
patients.12,13  
Our findings were independent of prognostic parameters for OS and PFS. Furthermore, the 
results of the current study revealed that TMT values provide information not captured by 
other possible explanatory variables. First, we found no significant correlation between WHO 
performance score and TMT. This might reflect the high observer variability regarding the 
patient’s physical condition which is mainly based on the subjective evaluation of the 
attending physician in contrast to TMT, which is an objectively assessable parameter 
estimating patient`s skeletal muscle mass. 8,16 Furthermore, the missing association between 
TMT and age indicates that skeletal muscle mass loss may yield more information about the 
patient`s physical condition than the chronological age alone. The findings of this study go in 





where TMT only showed a low negative correlation with patient´s age.18 Moreover, it is 
widely hypothesized that biological age, including patient´s frailty, is more highly associated 
with death than chronological age.27,28  Thus, based on the strong independent prognostic 
effect of TMT the parameter could be used as stratification factor in prospective clinical trials 
assessing the intensity of treatment intervention tailored to patient frailty.  
The results of this study suggest that TMT represents an objectively assessable parameter that 
may aid to improve the estimation of the prognosis of patients with recurrent glioblastoma. 
Despite the effect of Bevacizumab on PFS, there was no indication that baseline TMT is a 
predictive factor for PFS in relation to the treatment with either Bevacizumab alone versus 
Lomustine alone or the combination of Bevacizumab and Lomustine versus Lomustine alone 
both followed by the best investigators choice, as in both analyses the cutoff by treatment 
interaction term was not significant (results not shown). 
Amongst other cranio-facial muscles the thickness of the temporal muscle was selected in this 
study as prognostic parameter for several reasons. The temporal muscle is one of very few 
muscles that can be delineated in its full extent on routinely performed cranial MR images, 
which is of high importance particularly in patients which have undergone craniotomy or 
radiation therapy and may suffer from muscular edema or atrophy. Moreover, TMT has been 
shown in previous studies to correlate with skeletal muscle mass and may therefore be used to 
asses sarcopenia in patients with primary brain tumors, in whom usually only cranial MRI and 
no abdominal CT images are available.9,10,16 Furthermore, TMT has been shown to play a 
potential role in the prognosis of ventilator and hospital days in trauma patients and OS in 
newly diagnosed brain metastases patients.12,13,19 There is also a study that used temporal 
muscle volume to predict the length of the hospital stay in children with non-syndromic 
craniosynostosis.19,20 However, plane or volume segmentation is much more time-consuming 





corrections because it is still mostly prone to segmentation errors. In contrast, TMT 
measurements took only about 30 seconds per patient and its assessment is therefore an 
appropriate method for skeletal muscle mass estimation to be integrated in the routine clinical 
setting with a high inter-rater (left TMT 0.959; right TMT 0.975) and intra-rater agreement 
(left TMT 0.917; right TMT 0.94).10 The key benefit that the temporal muscle can be 
delimited in its whole extent on routinely assessed brain MR images comes along with the 
consequence to deal with a relatively small muscle diameter when it comes to TMT 
measurement. Therefore, it is all the more important to accurately adhere to the predefined 
landmarks and use only isotropic 1 x 1 x 1 mm MR images to provide a high measurement 
accuracy and minimize partial volume artifacts.10,12 To overcome the potential influence of 
oral or dental diseases on TMT, the measurements were taken on both sides and a mean TMT 
value was calculated in all patients. This did not show any signs of interventions (e.g. 
craniotomy) including the temporal muscle.21 
Although we were able to investigate and validate TMT in two cohorts of patients enrolled in 
a large international, prospective, randomized clinical trial, our study faces some limitations. 
The retrospective analysis of TMT prohibited evaluation of anatomical-functional 
relationships. Although recently published data revealed that TMT is an applicable parameter 
to estimate skeletal muscle mass, further studies are required to assess its correlation with 
clinical frailty parameters such as muscle strength in a prospective setting.10 Due to the fact, 
that we unexceptionally included progressive glioblastoma the measurement of bilateral 
temporal muscle thickness was only possible in 38% of the patients in this study cohort 
because of the frequent post-treatment changes including the temporal muscle at least at one 
side. Furthermore, in the current study we were able to investigate patients with progressive 
glioblastoma only. Thus, the validation of the defined cut-off value as well as the prognostic 





are currently working on the validation of the TMT cut-off in an external dataset consisting of 
newly diagnosed glioblastoma and will report these findings separately. We will use the cut-
off of 7.2 mm as a primary assumption but the identification of more optimal cut-off values 
per setting and disease will also be considered. Also owing to its retrospective nature, 
imbalances in important unmeasured prognostic factors or determinants of TMT could not be 
corrected for in the adjusted analyses. Moreover, although it is reported that ethnicity has an 
impact on skeletal muscle mass information about the ethnicity of the patients was not 
available in the current study. Therefore ethnic differences among the patients within the 
study cohort could not have been considered. Although the prognostic effect of TMT was 
independent from steroid use at baseline, the exact influence of duration and dose of steroid 
use on TMT remains to be determined in further studies, as these data were not available in 
our study population.  
The pathobiology of TMT variation among patients with recurrent glioblastoma remains 
unclear at the moment. TMT may reflect general physical fitness, or could also be associated 
with glioblastoma-related catabolic, paraneoplastic and inflammatory processes in 
combination with insufficient nutrition.22-24 In any case, the knowledge of the association 
between survival and skeletal muscle mass may result in additional therapeutic opportunities 
such as exercise training, nutritional supplements, or pharmacotherapy with myostatin 
inhibitors.25-28  
In conclusion, TMT is an independent prognostic parameter in patients with recurrent 
glioblastoma. Assessment of TMT may aid to optimize treatment decisions as well as patient 
stratification for clinical trials based on an objective determination of frail patient population. 
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Captions for all illustrations 
Figure 1: TMT assessment represented on cranial T1-weighted contrast-enhanced MR 
images. A, a 65-year-old female patient with an overall survival of 20.6 months (median TMT 
= 12.4 mm), and B, a 35-year-old male patient with an overall survival of 9.3 months (median 
TMT = 3.5 mm). 
Figure 2: Kaplan-Meier curve analysis according to mean TMT cutoff for OS (a) and PFS 
(b) in the training cohort. 
Figure 3: Kaplan-Meier curve analysis according to mean TMT cutoff for OS (a) and PFS 
(b) in the test cohort. 
 
 
 

